Oncimmune Appoints Lung Cancer KOL As Chief Medical Officer
This article was originally published in Clinica
Dr James Jett is to join Oncimmune, a company that has developed an early-stage lung cancer test, as chief medical officer on Jan 1. He is currently Professor of Medicine in the Division of Oncology at National Jewish Health in the US; he has been the principal investigator on the National Jewish Health study on Oncimmune’s blood-based autoantibody assay for early-stage lung cancer, Early CDT-Lung. In his role at the company, Jett will be responsible for overseeing all the R&D activities, as the firm continues to expand commercialization EarlyCDT-Lung. Oncimmune toldClinica earlier this year that it was ramping up US sales of the test. The firm is also developing tests for liver and ovarian cancers.